Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KYAN-001
- Development stage
- Preclinical
- Lead developer
- KYAN Technologies
- Modality
- Small Molecules
01
Overview
KYAN-001 is a selective Class II histone deacetylase (HDAC) inhibitor that specifically targets histone deacetylase 4 (HDAC4) and histone deacetylase 6 (HDAC6). Originally developed by Georgetown University and licensed to KYAN Technologies (formerly KYAN Therapeutics), this small molecule candidate is designed to inhibit HDAC4 nucleoshuttling and HDAC6 activity. Preclinical studies have demonstrated that KYAN-001 exhibits high efficacy and low toxicity compared to pan-HDAC inhibitors. Utilizing the Optim.AI platform, KYAN-001 has shown synergistic anti-cancer effects when combined with MEK inhibitors in KRAS-mutant solid tumors, such as prostate and pancreatic cancers, as well as monotherapy efficacy in multiple myeloma and patient-derived organoids.
02
Targets
HDAC4HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on KYAN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KYAN-001.